Merck Sharp & Dohme B.V.
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
31
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Crystal Forms of a CCR5 Antagonist (US 10,301,281) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 2, 2026The maintenance fee for FSH Receptor Antagonists (US 9,044,463) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 3 fees due Feb 11 to 25, 2027 · next Feb 11
- 3 fees due Mar 8 to 17, 2027 · next Mar 8
- 1 fee due May 3, 2027The maintenance fee for TSH Receptor Antagonizing Tetrahydroquinoline Compounds (US 9,174,940) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for ANTI-CD27 Antibodies (US 10,556,957) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 2 fees due Sep 22 to 24, 2027 · next Sep 22
Recent changes
- 5 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,618,985 | Isoquinoline Derivatives In force · High confidence | In force | High confidence | |
| US 11,040,184 | Kit for and Method of Assembling an Applicator for Inserting an Implant In force · High confidence | In force | High confidence | |
| US 10,821,277 | Kit for and Method of Assembling an Applicator for Inserting an Implant In force · Medium confidence | In force | Medium confidence | |
| US 7,820,649 | Quinazolinone and Isoquinolinone Acetamide Derivatives In force · High confidence | In force | High confidence | |
| US 7,906,504 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 8,722,037 | X-Ray Visible Drug Delivery Device In force · High confidence | In force | High confidence | |
| US 7,820,707 | Heterocyclic Derivatives In force · High confidence | In force | High confidence | |
| US 8,333,983 | Drug Delivery System In force · High confidence | In force | High confidence | |
| US 8,183,228 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label In force · Medium confidence | In force | Medium confidence | |
| US 8,168,595 | Antithrombotic Dual Inhibitors Comprising a Biotin Residue In force · High confidence | In force | High confidence |
Also on record, not counted in the 57: 20 patents in force now held by others · 50 lapsed for an unpaid fee · 94 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 abandoned